Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
Aranow C, Allaart C, Amoura Z, Bruce I, Cagnoli P, Chatham W, Clark K, Furie R, Groark J, Urowitz M, van Vollenhoven R, Daniels M, Fox N, Gregan Y, Henderson R, van Maurik A, Ocran-Appiah J, Oldham M, Roth D, Shanahan D, Tak P, Teng Y. Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. Annals Of The Rheumatic Diseases 2024, 83: ard-2024-225686. PMID: 39159997, PMCID: PMC11503042, DOI: 10.1136/ard-2024-225686.Peer-Reviewed Original ResearchSystemic lupus erythematosusProportion of patientsCycles of rituximabSubcutaneous belimumabLupus erythematosusSafety of sequential therapyModified intention-to-treat populationIntention-to-treat populationDisease control durationDisease controlInvestigation of combination treatmentsDisease activity markersAnti-dsDNA antibodiesDisease activity controlIntravenous placeboImmunosuppression withdrawalIntravenous rituximabSequential therapyClinical remissionStandard therapySecondary endpointsActivation markersAnti-dsDNARituximabPhase 3